Migraine Gains Cut Work Loss and Stigma Far Beyond Headache Days

Four in ten adults with migraine improved overall across one year in a large U.S. population study, and those gains reached well past fewer headache days. The improved group also logged lower disability, better quality of life, less workplace productivity loss, reduced stigma and lower medication needs.

Researchers drew on 11,634 adults who completed baseline and one-year surveys in the Observational survey of the Epidemiology, treatment, and Care Of MigrainE (OVERCOME) study. Status was judged by changes in monthly headache days, MIDAS disability scores and MSQ-RFR quality-of-life scores. At follow-up, 40.4% were overall improved, 24.1% overall worsened and 35.5% showed no net change.

That split matters because the same three measures moved together. When they did, work, stigma and treatment demand moved with them. When they did not, those secondary domains stayed largely flat as well.

What the One-Year Numbers Show

The improved group cut monthly headache days by a mean of 3.2 and MIDAS scores by 15.4 points while lifting MSQ-RFR scores by 13.7 points. The worsened group moved the opposite way: +3.4 headache days, +18.8 on MIDAS and -14.1 on MSQ-RFR.

In the improved cohort the share with little or no disability rose 28.6 percentage points to 63.2%. The share with 0-3 monthly headache days climbed 24.7 points to 75.6%. Worsened participants saw severe disability jump 27.9 points to 45.7% and the 15-plus headache-day group rise 11.6 points.

These figures come from the full OVERCOME 1-year results paper published in Neurology and Therapy. The no-net-change group stayed essentially flat on the three classifying measures.

The near-symmetry is hard to miss. Headache-day change ran -3.2 versus +3.4. MIDAS swung -15.4 versus +18.8. MSQ-RFR rose 13.7 or fell 14.1. The directions reverse, yet the magnitudes stay close. That pattern repeats in the share shifts for disability and high-frequency headache as well.

Together the mean changes and the share changes show that overall status is not a soft label. It tracks concrete movement on the same scales clinicians already use.

How Researchers Defined Real Change

Earlier longitudinal work often tracked only monthly headache days. OVERCOME used three domains at once and a simple points system. Improvement or worsening on each domain earned +1 or -1; net positive scores meant overall improved, net negative meant worsened, and zero meant no net change.

• Monthly headache days: improvement = ≥50% drop; worsening = ≥5-day rise
• MIDAS: improvement = ≥5-point drop (if baseline 11-20) or ≥30% drop (if baseline >20); worsening = ≥5-point rise
• MSQ-RFR: improvement = ≥25.71-point rise; worsening = ≥25.71-point drop

Those cut-offs rest on prior work showing clinical meaning for patients. Mixed results across domains often landed in the no-net-change bin, which kept the improved and worsened groups cleanly separated.

The design has a practical effect. A patient who drops headache days but loses ground on disability or role function does not count as overall improved. A patient who gains on quality of life yet climbs five or more headache days does not either. Only aligned movement across domains produces a net positive or net negative score. That is why the improved and worsened cohorts look so distinct on every secondary measure that follows.

Because 35.5% landed in the no-net-change group, the study also shows how common mixed or modest trajectories are in ordinary care. Flat scores on the three classifiers left work, stigma and medication need largely unchanged in that middle band as well.

The Productivity and Stigma Cascade

Work outcomes moved in lockstep with status. Improved participants cut daily activity impairment 8.4 percentage points, presenteeism 6.7 points and overall productivity loss 6.6 points on the Work Productivity and Activity Impairment questionnaire. Worsened participants saw the reverse rises of 9.2, 7.9 and 8.0 points.

Stigma followed the same pattern. The share of improved participants who never experienced migraine-related stigma rose 11.8 points to 25.3%. The share who hid their condition fell 11.5 points to 57.7%. Earlier OVERCOME work had already shown that frequent stigma tracks with higher disability and lower quality of life; the one-year data show stigma itself can ease when overall status improves.

Key workplace and stigma shifts in the improved group

• Activity impairment: 43.6% → 35.2%
• Presenteeism: 41.1% → 34.4%
• Never experience stigma: 13.5% → 25.3%
• Hide migraine: 69.2% → 57.7%

U.S. employers already absorb heavy indirect costs from migraine. Older national estimates put lost productive time near $19 billion a year, and employer models of migraine lost productive time show indirect costs often run several times direct medical spend. The new data suggest those losses shrink measurably once status improves.

Presenteeism deserves special weight here. The improved group moved from 41.1% to 34.4% on that measure, a 6.7-point drop that matches the broader productivity-loss decline of 6.6 points. People were not only missing less work; they were functioning better while at work. The worsened group’s presenteeism rise of 7.9 points shows the same pathway running in reverse.

Medication Needs Fall When Status Rises

Treatment demand tracked the same direction. In the improved group the share with no medication need rose 26.6 points to 46.1%. The share needing both acute and preventive drugs fell 24.6 points to 17.7%. Overuse of OTC medicines and NSAIDs also dropped. The worsened group moved the opposite way: no-need share fell 18 points and dual-need share climbed 26.7 points to 58.9%.

Use of recommended acute medicines declined across all three status groups, while preventive use stayed flat. Acute medication efficacy scores showed little change. The pattern implies that status improvement itself reduces the pressure for more drugs and the risk of overuse, even before new prescriptions appear.

• Improved: lower acute + preventive need, less OTC/NSAID overuse
• Worsened: higher dual medication need
• All groups: lower recommended acute use, stable preventives

The dual-need contrast is especially sharp. Improved participants ended at 17.7% on combined acute-plus-preventive therapy. Worsened participants ended at 58.9%. That gap opened in a single year without a corresponding jump in preventive uptake across the full sample. Status change, not a wave of new preventive starts, appears to be what shifted demand.

Broader Function Moves With the Core Scores

Domains outside the classification rules still shifted. MSQ role-function preventive and emotional-function scores rose roughly 11 points in the improved group and fell roughly 10-11 points in the worsened group. Headache pain severity eased 0.9 points among the improved. Interictal burden (symptoms between attacks) grew more severe among those who worsened, with the severe-burden share up 12.1 points.

Daily functioning ratings improved modestly in the better group. Depression and anxiety symptom scores on the PHQ-4 did not change much inside either group, yet the between-group difference favored those who improved. The cascade is consistent: when the three core measures move together, emotional, interictal and work domains tend to follow.

• MSQ role-function preventive and emotional-function: ~+11 improved, ~-10 to -11 worsened
• Headache pain severity: -0.9 among improved
• Severe interictal burden: +12.1 pp among worsened
• PHQ-4 mood scores: little within-group change, between-group edge to improvers

Interictal burden is easy to overlook in clinic visits that focus on attack days. The 12.1-point rise in severe between-attack burden among those who worsened shows that deterioration is not confined to the headache itself. The reverse ease in pain severity among improvers, though modest at 0.9 points, fits the same broad lift.

Why Clinics Should Track More Than Headache Days

Migraine already ranks among the top causes of years lived with disability worldwide and the second-leading cause among women aged 15-49. Roughly 12-15% of U.S. adults live with it. Most care still happens in primary care rather than specialty clinics. The OVERCOME classification shows that a simple three-measure score captures real-world change better than headache days alone.

Prior OVERCOME waves found that 31.7% of people with migraine experience related stigma often or very often, and that stigma links tightly to disability. The earlier OVERCOME findings on migraine stigma make the one-year drop in stigma among improvers especially practical: status gains can loosen the social load as well as the physical one.

This study demonstrates the profound effect of improvement or worsening of migraine symptoms on workplace productivity, migraine-related stigma, physical function, and need for treatment.

That conclusion, from lead author Dawn C. Buse and colleagues, points straight at clinical practice. Timely diagnosis and treatment optimization are not only about cutting attack frequency. They are also about protecting work capacity, reducing concealment, and lowering the chance that patients drift into higher medication demand and heavier disability.

Crowd conversation around migraine and work still circles the same gap: presenteeism is large, yet many workplaces still treat migraine as occasional sick days rather than a neurological condition that benefits from flexible support. The new data give employers and clinicians a clearer target. When overall status improves, the productivity and stigma numbers move with it. When status worsens, the reverse is equally clear.

The study cannot prove that any single drug or lifestyle change caused the gains; it is observational. Yet the size of the cohort, the demographically representative sampling, and the multi-domain consistency make the pattern hard to ignore. For patients and clinicians the practical message is simple. Measure more than headache days. Act early. The returns in function, work and social life are large enough to matter.

What the One-Year Split Means for Care

Four in ten improved. Roughly one in four worsened. Just over one in three held steady. Those proportions come from a demographically representative U.S. sample of 11,634 adults, not a specialty-clinic panel, so they sketch the ordinary course of migraine across a year of usual care.

Primary care teams see most of these patients. A three-domain score built from headache days, MIDAS and MSQ-RFR does not require new technology. It does require asking about disability and role function at follow-up, not only attack counts. The payoff is cleaner separation of who is truly better, who is drifting, and who needs a faster change in plan.

The medication findings reinforce that point. Dual acute-plus-preventive need fell 24.6 points among improvers and rose 26.7 points among those who worsened. OTC and NSAID overuse eased only in the improved group. Waiting for headache days alone to declare failure can leave patients on a path toward heavier drug demand and higher disability before anyone revisits the regimen.

Employers hold a parallel stake. Indirect costs already dwarf direct medical spend in published models, and national lost-productive-time estimates near $19 billion a year set the scale. The WPAI shifts here (activity impairment -8.4 pp improved versus +9.2 pp worsened; presenteeism -6.7 versus +7.9) show those losses are not fixed. They move when overall clinical status moves.

How Stigma Relief Follows Clinical Gains

Stigma is often treated as a fixed social fact. The one-year OVERCOME data push back. Among improvers, the share who never experienced migraine-related stigma nearly doubled in relative terms, rising 11.8 points to 25.3%. The share who hid their condition fell 11.5 points to 57.7%.

Earlier OVERCOME waves had already tied frequent stigma (31.7% often or very often) to higher disability and lower quality of life. The new results close the loop in the other direction. When disability and quality-of-life scores improve alongside headache days, concealment and stigma exposure ease too.

That sequence has clinic and workplace implications. Reducing attack burden is not only a neurological goal. It is also a route to less hiding and less social friction, which in turn can make it easier for patients to seek timely care and to request reasonable flexibility at work. The cascade runs both ways: better status lightens stigma, and lighter stigma removes one barrier to staying in care.

Frequently Asked Questions

What percentage of people with migraine improved in the OVERCOME one-year study?

Exactly 40.4% of the 11,634 adults who completed both surveys were classified as overall improved, 24.1% as overall worsened, and 35.5% as no net change when monthly headache days, MIDAS and MSQ-RFR were combined.

How did researchers decide if migraine status improved or worsened?

They awarded +1 for meeting improvement cut-offs and -1 for worsening cut-offs on each of three measures, then summed the points. Net positive equaled overall improved; net negative equaled overall worsened. The specific thresholds were a ≥50% drop or ≥5-day rise in monthly headache days, clinically meaningful MIDAS shifts of 5 points or 30%, and a 25.71-point swing on MSQ-RFR.

Did workplace productivity improve only when headache days fell?

No. Productivity, presenteeism and activity impairment improved in the overall-improved group even though the classification also required disability and quality-of-life gains. The WPAI reductions (roughly 7 percentage points across domains) therefore reflect the multi-measure status change, not headache days alone.

What happened to medication overuse when migraine improved?

Over-the-counter medication overuse fell 8.3 percentage points and NSAID overuse fell 6.0 points in the improved group. Dual acute-plus-preventive need also dropped sharply, while the worsened group saw dual need rise more than 26 points.

Is the OVERCOME study a clinical trial of a specific treatment?

No. It is a web-based longitudinal observational survey of a demographically representative U.S. sample recruited in waves from 2018-2020. Participants completed validated questionnaires; the analysis describes natural change over one year rather than the effect of any single intervention.